A Study in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma

What's the purpose of this trial?

This is a first-in-human (FIH), 2-part, open-label, multi-center, Phase 1/1b safety, tolerability, pharmacokinetics (PK), and efficacy study of oral SETD2 inhibitor, EZM0414, in subjects with relapsed/refractory (R/R) Multiple Myeloma (MM) and R/R Diffuse Large B-Cell Lymphoma (DLBCL).

This is an upcoming trial that has not yet started accepting patients.


What will happen during the trial?

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

  • Voluntarily provide signed informed consent after review of verbal and written material about the trial and agree to abide with protocol requirements. All study related activities must be carried out after written consent is obtained.
  • Subjects must be ≥18 years of age at the time of signing the ICF (Informed Consent Form).
  • Subjects must have an Eastern Cooperative Oncology Group status of 0 or 1.
  • For MM, subjects must have measurable disease by IMWG (International Myeloma Working Group) 2016 criteria
  • For DLBCL, subjects must have measurable disease by Lugano criteria
  • Females must not be breastfeeding or pregnant at screening
  • Females of childbearing potential must not have had unprotected sexual intercourse while participating in this study
  • Male subjects must have had either a successful vasectomy OR they and their female partner must meet the criteria above ie, not of childbearing potential OR practicing highly effective contraception and use a condom throughout the study period

Exclusion Criteria:

  • Subjects with plasma cell leukemia defined as a plasma cell count >2000/mm3.
  • Subjects with Waldenstrom's macroglobulinemia or smoldering MM.
  • Subjects who had prior treatment with SETD2 or NSD2 inhibitor.
  • Subjects with active acute or chronic systemic infection requiring systemic treatment, including COVID-19.
  • Has cardiovascular impairment
  • Prolongation of corrected QT interval using Fridericia's formula (QTcF) to > 480 msec or history of long QT syndrome.
  • Known left ventricular ejection fraction (LVEF) < 50% by either echocardiogram (ECHO) or multigated acquisition (MUGA).
  • Prior major surgery within 4 weeks of treatment start.
  • Known hypersensitivity to components of the investigational product.
  • Subjects who have received treatment with any unapproved drug product within 4 weeks prior to screening.
  • Current participation in any other interventional clinical study except for follow up.
  • Subjects with a history of or active malignancy other than disease under study
  • Underlying medical/social conditions that in PI opinion will place the subject in significant risk and affect the interpretation of toxicity and adverse events assessments.
  • Inability to take oral medication or known gastrointestinal (GI) disease, GI procedure or medical condition that could interfere with the oral absorption or tolerance of the study drug

Additional Trial Information

Phase 1

Enrollment: 96 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Massachusetts

Dana-Farber Cancer Institute

Boston, MA

Not Yet Accepting

New York

Weill Cornell Medicine

New York, NY

Not Yet Accepting

Texas

MD Anderson Cancer Center The University of Texas

Houston, TX

Not Yet Accepting

Trial Links

Read the latest news and updates on this trial.

Epizyme Receives Fast Track Designation from U.S. FDA and Announces Initiation of Phase 1/1b Study of its Novel SETD2 Inhibitor, EZM0414

November 04, 2021

Epizyme, Inc., a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to EZM0414, the Company’s novel, first-in-class, oral SETD2 inhibitor, as an investigational agent for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Read more
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message